×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular ...
PR Newswire
PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that preclinical data for agents...
8 months ago
Lilly $8bn Loxo speedy buy 'not competitive,' says analyst
BioProcess International
It took Eli Lilly 18 days from expressing its interest in Loxo Oncology to executing an $8 billion merger agreement. Being a “significant premium over the...
3 months ago
Lilly Announces Agreement To Acquire Loxo Oncology | Eli Lilly and Company
Eli Lilly and Company
Lilly Announces Agreement To Acquire Loxo Oncology ... Eli Lilly and Company (NYSE: LLY) and Loxo Oncology, Inc. (NASDAQ: LOXO) today announced a...
64 months ago
Eli Lilly axes next-generation, resistance-busting RET inhibitor
Fierce Biotech
Lilly pushed the candidate, LOXO-260, into the clinic to overcome acquired resistance to existing drugs such as its own Retevmo.
4 months ago
Eli Lilly Acquiring Cancer Therapy Developer For $1.4 Billion—A Nearly 90% Premium
Forbes
American pharmaceutical company Eli Lilly plans to acquire cancer therapy firm Point Biopharma Global, the companies announced Tuesday,...
8 months ago
The Next Wave of ADCs Could Treat Evasive Solid Tumors
BioSpace
With second-generation antibody-drug conjugates, Eli Lilly, Daiichi Sankyo and others look to reduce toxicity and improve the magnitude and...
1 month ago
Elli Lilly Cancer Drug Lands Its Second FDA Approval This Year
MedCity News
Eli Lilly cancer drug Jaypirca is closing 2023 the same way it started—with an FDA approval. The latest regulatory nod adds two additional...
6 months ago
Race for Better Mutant PI3Kα Inhibitors Hinges on Disputed Science
Precision Medicine Online
Data from upcoming clinical trials may answer fundamental questions about the anti-cancer mechanisms of PI3Kα inhibitors and the...
5 months ago
Foghorn's shares rise after Lilly chooses cancer drug for development - Boston Business Journal
The Business Journals
Foghorn Therapeutics saw its stock price soar on Thursday following the news that its collaboration with Loxo Oncology at Lilly,...
3 months ago
Eli Lilly to buy Loxo Oncology for $8 billion in huge bet on cancer genetics
www.statnews.com
The pharmaceutical giant will purchase Loxo Oncology, a tiny startup, for $8 billion in cash to gain access to the company's cancer...
64 months ago